ABVX Trading Analysis - 10/23/2026 04:17 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge headlines and context for ABVX (Abivax SA), a clinical-stage biotech focused on inflammatory disease therapies:

• Abivax reported updated Phase 3 trial data for obefazimod in ulcerative colitis, with regulatory submission discussions ongoing in the EU and US (general knowledge).
• Company completed a follow-on financing round earlier in 2026 to extend cash runway toward anticipated approval milestones (general knowledge).
• Biotech sector saw heightened volatility around FDA advisory panel calendars and competitive readouts from peer inflammatory bowel disease assets (general knowledge).
• No confirmed near-term earnings catalyst in embedded data; fiscal year end listed as 2025-12-01 with no ex-dividend or dividend events.

Context: Positive pipeline headlines may help explain the bullish delta 40-60 options flow, even as price remains below major moving averages and technicals read bearish. This divergence mirrors the spread engine's noted misalignment.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing EPS is -5.85; company is unprofitable with no trailing P/E (null) and no forward P/E (null).
• PEG ratio, profit margins, ROE, revenue, and free cash flow are all null — not disclosed in data.
• Market cap is 7,682,990,520.00 with shares outstanding of 87,272,000.00.
• Dividend yield 0.00; no dividend rate or ex-dividend date.
• Institutional ownership is only 12.91% — low sponsorship versus typical large caps.
• 52-week range: 69.81 low to 148.83 high; current price near lower third of that range.
• Historical volatility 53.85%; average volume 1,316,000.00.
• No analyst target mean price or recommendation key provided.

Fundamentals show a pre-revenue, loss-making biotech with thin institutional base. This contrasts with bullish options sentiment and aligns with weak technicals (price below SMAs, bearish MACD).

Current Market Position

Current price per indicators is 89.75 (2026-10-22 close). Minute bars show 2026-10-23 15:45 close at 87.83, down from 92.23 open on 2026-10-22 09:30. Last five minute bars trend lower: 88.01 → 87.81 → 87.83 → 87.76 → 87.83.

Daily history: 2026-09-11 close 118.64 → 2026-10-22 close 89.75, a decline of ~24.4%. 30-day range high 119.02, low 84.11.

Technical Analysis

Price below all SMAs; 5 < 20 < 50 bearish alignment. RSI 45.08 neutral-weak. MACD negative with histogram -0.81 confirms bearish momentum. Bollinger middle 91.03, price near lower half. 30-day low 84.11, high 119.02; price at ~14% above low.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via tru-sentiment methodology shows:

Call Volume: 491,490.00 (87.00%) Put Volume: 73,120.00 (13.00%) Total: 564,610.00

Sentiment: Bullish. Call contracts 663 vs put 92. Pure directional conviction strongly favors calls, suggesting near-term upside expectations despite bearish technicals. Spread engine flagged divergence: "Options sentiment is Bullish but technicals are Bearish."

Key Price Levels (observational only)